Cargando…
Master protocols: New directions in drug discovery
A master protocol is a unifying study construct that includes multiple subgroups and substudies, with patients having same or different diseases and that employ one or multiple drugs to treat it. Initially designed for oncology, master protocol trials are intended to simultaneously evaluate more tha...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205752/ https://www.ncbi.nlm.nih.gov/pubmed/32395664 http://dx.doi.org/10.1016/j.conctc.2020.100568 |
_version_ | 1783530298180370432 |
---|---|
author | Bogin, Vladimir |
author_facet | Bogin, Vladimir |
author_sort | Bogin, Vladimir |
collection | PubMed |
description | A master protocol is a unifying study construct that includes multiple subgroups and substudies, with patients having same or different diseases and that employ one or multiple drugs to treat it. Initially designed for oncology, master protocol trials are intended to simultaneously evaluate more than one investigational drug and/or more than one cancer type within the same overall trial structure. The ability to use a single infrastructure, trial design, and protocol to simultaneously evaluate multiple drugs and/or disease populations in multiple substudies, speeds up drug development and makes it more efficient. Thus, it is important for the clinical trial professionals to understand both the basic principles of master protocol trials and the way innovative trial designs are starting to change the landscape of clinical research. |
format | Online Article Text |
id | pubmed-7205752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-72057522020-05-11 Master protocols: New directions in drug discovery Bogin, Vladimir Contemp Clin Trials Commun Article A master protocol is a unifying study construct that includes multiple subgroups and substudies, with patients having same or different diseases and that employ one or multiple drugs to treat it. Initially designed for oncology, master protocol trials are intended to simultaneously evaluate more than one investigational drug and/or more than one cancer type within the same overall trial structure. The ability to use a single infrastructure, trial design, and protocol to simultaneously evaluate multiple drugs and/or disease populations in multiple substudies, speeds up drug development and makes it more efficient. Thus, it is important for the clinical trial professionals to understand both the basic principles of master protocol trials and the way innovative trial designs are starting to change the landscape of clinical research. Elsevier 2020-04-25 /pmc/articles/PMC7205752/ /pubmed/32395664 http://dx.doi.org/10.1016/j.conctc.2020.100568 Text en © 2020 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Bogin, Vladimir Master protocols: New directions in drug discovery |
title | Master protocols: New directions in drug discovery |
title_full | Master protocols: New directions in drug discovery |
title_fullStr | Master protocols: New directions in drug discovery |
title_full_unstemmed | Master protocols: New directions in drug discovery |
title_short | Master protocols: New directions in drug discovery |
title_sort | master protocols: new directions in drug discovery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205752/ https://www.ncbi.nlm.nih.gov/pubmed/32395664 http://dx.doi.org/10.1016/j.conctc.2020.100568 |
work_keys_str_mv | AT boginvladimir masterprotocolsnewdirectionsindrugdiscovery |